In addition to these signaling pathway alterations, increased expression of the WNT5A ligand, which is well known to promote melanoma progression [12,13], has been observed in BRAFi-R melanoma cells and in tumor tissue from a majority of patients with acquired BRAFi resistance. Here, WNT5A is linked to melanoma.